BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36572384)

  • 1. An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.
    Tokaz MC; Baldomero H; Cowan AJ; Saber W; Greinix H; Koh MBC; Kröger N; Mohty M; Galeano S; Okamoto S; Chaudhri N; Karduss AJ; Ciceri F; Colturato VAR; Corbacioglu S; Elhaddad A; Force LM; Frutos C; León AG; Hamad N; Hamerschlak N; He N; Ho A; Huang XJ; Jacobs B; Kim HJ; Iida M; Lehmann L; de Latour RP; Percival MM; Perdomo M; Rasheed W; Schultz KR; Seber A; Ko BS; Simione AJ; Srivastava A; Szer J; Wood WA; Kodera Y; Nagler A; Snowden JA; Weisdorf D; Passweg J; Pasquini MC; Sureda A; Atsuta Y; Aljurf M; Niederwieser D
    Transplant Cell Ther; 2023 Apr; 29(4):279.e1-279.e10. PubMed ID: 36572384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
    Brissot E; Labopin M; Stelljes M; Ehninger G; Schwerdtfeger R; Finke J; Kolb HJ; Ganser A; Schäfer-Eckart K; Zander AR; Bunjes D; Mielke S; Bethge WA; Milpied N; Kalhs P; Blau IW; Kröger N; Vitek A; Gramatzki M; Holler E; Schmid C; Esteve J; Mohty M; Nagler A
    J Hematol Oncol; 2017 Jun; 10(1):130. PubMed ID: 28646908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011-2012: A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT).
    Aljurf M; Nassar A; Hamidieh AA; Elhaddad A; Hamladji RM; Bazarbachi A; Ibrahim A; Ben Othman T; Abdel-Rahman F; Alseraihy A; Fahmy O; Hussein AA; Alabdulaaly A; Adil S; Alkindi SS; Bayoumy M; Dennison D; Bekadja MA; Redhouane AN; Rasheed W; AlSagheir A; Alsudairy R; Ladeb S; Benchekroun S; Ramzi M; Ahmed P; ElSolh H; Ahmed SO; Hussain F; Ghavamzadeh A
    Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):167-75. PubMed ID: 26452331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2008-2009: report on behalf of the Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group.
    Mohamed SY; Fadhil I; Hamladji RM; Hamidieh AA; Fahmy O; Ladeb S; Alimoghaddam K; Elhaddad A; Nacer RA; Alsharif F; Rasheed W; Jahani M; Mousavi SA; Alseraihy A; Abdel-Rahman F; Al Jefri A; Hussein AA; Alabdulaaly A; Ibrahim A; Bekadja MA; Abboud M; Ahmed P; Dennison D; Bakr M; Benchekroun S; Hussain F; Othman TB; Aljurf M; Ghavamzadeh A
    Hematol Oncol Stem Cell Ther; 2011; 4(2):81-93. PubMed ID: 21727769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients.
    Cho BS; Yahng SA; Min GJ; Park S; Park SS; Shin SH; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
    Transplant Cell Ther; 2021 Sep; 27(9):774.e1-774.e12. PubMed ID: 34082159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison.
    Devillier R; Legrand F; Rey J; Castagna L; Fürst S; Granata A; Charbonnier A; Harbi S; d'Incan E; Pagliardini T; Faucher C; Lemarie C; Saillard C; Calmels B; Mohty B; Maisano V; Weiller PJ; Chabannon C; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1449-1454. PubMed ID: 29448057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents with Acute Myeloid Leukemia in Brazil: A Multicentric Retrospective Study.
    de Melo Rodrigues AL; Bonfim C; Seber A; Colturato VAR; Zecchin VG; Nichele S; Daudt LE; Fernandes JF; Vieira AK; Darrigo Junior LG; Gomes AA; Arcuri L; Lenzi L; Picharski GL; Ribeiro RC; de Figueiredo BC
    Cell Transplant; 2020; 29():963689720949175. PubMed ID: 32787568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extramedullary relapse of acute leukemia after allogeneic hematopoietic stem cell transplantation: different characteristics between acute myelogenous leukemia and acute lymphoblastic leukemia.
    Ge L; Ye F; Mao X; Chen J; Sun A; Zhu X; Qiu H; Jin Z; Miao M; Fu C; Ma X; Chen F; Xue S; Ruan C; Wu D; Tang X
    Biol Blood Marrow Transplant; 2014 Jul; 20(7):1040-7. PubMed ID: 24704575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of allogeneic hematopoietic stem cell transplantation from matched siblings or unrelated donors during the first complete remission in patients with cytogenetically normal acute myeloid leukemia.
    Hsieh YY; Hong YC; Hsiao LT; Yu YB; Liu JH; Gau JP; Lin HN; Hsu YN; Chiou TJ; Chen PM; Tzeng CH; Liu CY
    Eur J Haematol; 2011 Mar; 86(3):237-45. PubMed ID: 21155895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial.
    Hyakuna N; Hashii Y; Ishida H; Umeda K; Takahashi Y; Nagasawa M; Yabe H; Nakazawa Y; Koh K; Goto H; Fujisaki H; Matsumoto K; Kakuda H; Yano M; Tawa A; Tomizawa D; Taga T; Adachi S; Kato K
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27875. PubMed ID: 31309713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors.
    Niederwieser D; Baldomero H; Bazuaye N; Bupp C; Chaudhri N; Corbacioglu S; Elhaddad A; Frutos C; Galeano S; Hamad N; Hamidieh AA; Hashmi S; Ho A; Horowitz MM; Iida M; Jaimovich G; Karduss A; Kodera Y; Kröger N; Péffault de Latour R; Lee JW; Martínez-Rolón J; Pasquini MC; Passweg J; Paulson K; Seber A; Snowden JA; Srivastava A; Szer J; Weisdorf D; Worel N; Koh MBC; Aljurf M; Greinix H; Atsuta Y; Saber W
    Haematologica; 2022 May; 107(5):1045-1053. PubMed ID: 34382386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation.
    Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of publication to TBI burden ratio of low- and middle-income countries versus high-income countries: how can we improve worldwide care of TBI?
    Tropeano MP; Spaggiari R; Ileyassoff H; Park KB; Kolias AG; Hutchinson PJ; Servadei F
    Neurosurg Focus; 2019 Nov; 47(5):E5. PubMed ID: 31675715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia.
    Ock CY; Seo H; Kim DY; Min BJ; Park Y; Cheong HS; Kim HL; Song EY; Kim I; Yoon SS; Kim JH; Koh Y
    Leuk Lymphoma; 2019 Jul; 60(7):1775-1781. PubMed ID: 30507323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic stem cell transplantation: a global perspective.
    Gratwohl A; Baldomero H; Aljurf M; Pasquini MC; Bouzas LF; Yoshimi A; Szer J; Lipton J; Schwendener A; Gratwohl M; Frauendorfer K; Niederwieser D; Horowitz M; Kodera Y;
    JAMA; 2010 Apr; 303(16):1617-24. PubMed ID: 20424252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant.
    Blau IW; Basara N; Bischoff M; Günzelmann S; Römer E; Kirsten D; Schmetzer B; Kiehl MG; Fauser AA
    Bone Marrow Transplant; 2000 Jan; 25(1):41-5. PubMed ID: 10654013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of NCCN (2015) risk stratification on prognosis of patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Lu Y; Wu T; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Wang H; Liu HX; Wang T; Tong CR; Ji SQ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):44-49. PubMed ID: 28219225
    [No Abstract]   [Full Text] [Related]  

  • 20. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.